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ABSTRACT
To evaluate whether tumour-derived microvesicles (T-MV), originating from the plasma
membrane, represent suitable cancer biomarkers, we isolated MV from peripheral blood
samples of cancer patients with locally advanced and/or metastatic solid tumours (n = 330,
including 79 head & neck cancers, 74 lung cancers, 41 breast cancers, 28 colorectal cancers
and 108 with other cancer forms) and controls (n = 103). Whole MV preparations were
characterised using flow cytometry. While MV carrying the tumour-associated proteins
MUC1, EGFR and EpCAM were found to be enhanced in a tumour-subtype-specific way in
patients’ blood, expression of the matrix metalloproteinase inducer EMMPRIN was increased
independent of tumour type. Higher levels of EMMPRIN+-MV correlated significantly with
poor overall survival, whereas the other markers were prognostic only in specific tumour
subgroups. By combining all four tumour-associated antigens, cancer patients were sepa-
rated from healthy controls with an AUC of up to 0.85. Ex vivo, whole MV preparations from
cancer patients, in contrast to those of controls, induced a tumour-supporting phenotype in
macrophages and increased tumour cell invasion, which was dependent on the highly
glycosylated isoform of EMMPRIN. In conclusion, the detection of T-MV in whole blood,
even in minor amounts, is feasible with standard techniques, proves functionally relevant
and correlates with clinical outcome.
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Extracellular vesicles (EV) are increasingly recognised as
important mediators in cellular communication. The two
main populations of EV shed by living cells are exosomes
(Exo, diameter 30–100 nm) formed by inward budding of
endosomal membranes and released upon the fusion of
multivesicular bodies with the plasma membrane, and
microvesicles (MV, diameter 100–1000 nm) that bud off
directly from the cell membrane [1].
Over the last few years it has become apparent that EV
play important roles in various human diseases including
cancer. Recent studies have demonstrated that cancer
cells can stimulate themselves with their own EV leading
to increased tumour invasion, migration or proliferation
[2–4]. In vitro studies have revealed that cancer-derived
EV interact with the surrounding microenvironment,
including immune cells, in which they can induce a
tumour-supporting phenotype [5–7]. In vivo, the injec-
tion of tumour-cell-derived EV (T-EV) in mouse models
of skin and pancreatic cancer leads to an accumulation of
the vesicles in lymph nodes, lung tissue as well as in the
bone marrow, in which they support the creation of pre-
metastatic niches [8–10].
T-EV harbour a plethora of proteins that are often
enriched in comparison with their cell of origin.
Among them are many tumour-associated proteins
such as epithelial cell adhesion molecule (EpCAM)
which has allowed detection of tumour-derived Exo
in blood of ovarian cancer patients [11]. Also epithelial
growth factor receptor (EGFR) has been found on
exosomes from brain tumour cells [12] and was
shown to induce a pro-angiogenic phenotype when
transferred on T-EV to endothelial cells [13]. Other
tumour-associated proteins found on T-EV include
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CD47 [14], Mucin 1 (MUC1/CA 15–3) [2,15] or extra-
cellular matrix metalloproteinase inducer (EMMPRIN/
CD147), which promotes tumour invasion when
expressed in its highly-glycosylated isoform on
tumour-derived MV (T-MV) [2]. Taken together,
these tumour-associated antigens provide a whole
panel of potential biomarkers. This is particularly pro-
mising for the identification of tumour cell signatures
in peripheral blood, in contrast to the evaluation of
individual secreted proteins. EV have already been iso-
lated from various human body fluids including saliva,
breast milk, ascites, cerebrospinal fluid (CSF), and per-
ipheral blood (overview in [16]). Recently, the smaller
Exo were identified as novel biomarkers in early-stage
pancreatic and breast cancer in patients’ blood [17,18].
Moreover, the analysis of Exo from blood allows real-
time monitoring of glioblastoma therapy [19].
However, the isolation and analysis of Exo is time
consuming and requires special equipment. In contrast,
due to their larger size, MV can easily be isolated from
peripheral blood and characterised by flow cytometry,
a technique routinely used for diagnostic purposes in
most clinical centres.
Thus, the initial aim of this study was to define
suitable markers that would allow the detection and
comparative analysis of the various MV populations
present in the peripheral blood of cancer patients and
controls using an approach based on flow cytometry.
This was performed with samples from our vesicle
biobank containing blood taken from cancer patients
suffering from metastatic disease originating from a
number of different types of solid tumour, as well as
from controls. These results were subsequently corre-
lated with clinical parameters and subjected to func-
tional analysis ex vivo. Our second aim here was to
further define the role of T-MV present in cancer
patients’ blood in tumour progression in vivo and to
evaluate whether T-MV are suitable as biomarkers.
Materials and methods
Patients
All human samples were collected after obtaining
informed consent as approved by the local ethics com-
mittee (approval no. 3/2/14). Peripheral blood samples
were drawn either from cancer patients with various
types of solid tumour (n = 330), healthy individuals
(n = 62) or non-healthy patients (n = 41) (Tables 1 and
2). The healthy controls were mostly blood donors,
whereas the non-healthy control group comprised
patients with benign diseases, e.g. heart and kidney
disease, diabetes or infections, as well as patients who
were in long-lasting remission after treatment for hae-
matological neoplasms. A few patients with indolent
lymphomas under watch and wait strategy were also
included in the non-healthy controls. Details of all
groups are presented in Table 1 and 2.
The samples were obtained prior to treatment in order
tominimise contaminationwith apoptotic vesicles. At the
point in time of blood collection, cancer patients were
staged as follows: Union for International Cancer Control
(UICC) I, 18 patients; UICC II, 25 patients; UICC III, 35
patients; UICC IV, 126 patients (no UICC data available
for 125 patients). The overall survival (OS) had a time to
50% at risk of 7.38 months (95% confidence interval (CI)
6.69–8.3). Follow-up examinations were performed at the
discretion of individual physicians and the data were
obtained either from the local clinical cancer registry or
the physician responsible for the patient. OS was defined
as the duration from the time at which blood samples
were taken and cancer-related death.
Table 1. Characterisation of the cohort.
Samples n
Age [years]
Classification: Median [95% CI]
Gender
Classification: male [%]
Cancer patients 330 64.85 [63.33–65.71] 57.3 (187/330)
head and neck cancer 79 64.78 [62.41–66.47] 78.5 (62/79)
lung cancer 74 64.85 [62.26–67.16] 56.8 (42/74)
breast cancer 41 64.28 [60.40–67.47] 4.9 (2/41)
multiple solid tumours 35 66.12 [63.26–69.25] 62.9 (22/35)
colorectal cancer 28 65.32 [57.69–67.94] 57.1 (16/28)
brain tumours 16 66.31 [56.92–72.99] 56.3 (9/16)
skin cancer 14 64.14 [56.68–78.47] 78.6 (11/14)
CUP 14 70.40 [60.26–77.79] 50.0 (7/14)
urogenital cancer 8 65.32 [55.86–74.93] 75.0 (6/8)
others 21 61.12 [57.70–68.77] 57.1 (12/21)
Healthy controls 62 36.12 [35.93–42.57] 58.1 (36/62)
Non-healthy controls 41 66.38 [62.59–69.69] 39.0 (16/41)
The patient cohort was characterised according to listed parameters in the header. Type of classification and distribution within the cohort is given for each
parameter for all three groups. For cancer patients the distribution of underlying diagnosis is given in the second column. CUP: Cancer of Unknown
Primary.










































Human MCF-7, MDA-MB-231 and SK-BR-3 breast
cancer, A549 lung cancer as well as SW480 colorectal
cancer cells (obtained from ATCC) were cultured in
RPMI-1640 medium supplemented with 10% foetal calf
serum (FCS). Platelets and red blood cells were
obtained from concentrates kindly provided by the
Department of Transfusion Medicine at the
University Medical Centre Göttingen. Human macro-
phages were obtained from monocytes that had been
isolated from Buffy coats and were differentiated with
macrophage colony-stimulating factor (M-CSF) as
described previously [20].
Antibodies
To characterise MV flow cytometrically, the following
antibodies were used: CD45 (J33, #A07782), CD235a
(11E4B-7–6, #A07792, both Beckman Coulter), CD62P
(AK4, #304905), CD47 (CC2C6, #323109), MUC1
(16A, #355604) EGFR (AY13, #352904), EMMPRIN
(HIM6, #306207), CD62E (HAE-1f, #336008),
EpCAM (9C4, #324208, all from Biolegend). To ana-
lyse CD63 expression, vesicles were incubated with the
unlabelled CD63 antibody (H5C6, #556019, BD) or
mouse IgG (#sc-2025, Santa Cruz Biotechnology) and
signals visualised using a FITC-labelled secondary anti-
body (#sc-2010, Santa Cruz Biotechnology). Protein
expression by Western Blotting was assessed using
primary antibodies against EMMPRIN (H200, #sc-
13976), MUC1 (VU4H5, #sc-7313), Tsg101 (C-2, #sc-
7964), Hsp90 (F-8, #sc-13119, all from Santa Cruz
Biotechnology), HDAC1 (#2062), EGFR, (D38B1,
#4267, both from Cell Signaling), CD9 (MEM-61,
#21270091, Immunotools), CD81 (5A6, #349501,
Biolegend), Wnt5a (442625, #MAB645, R&D systems),
syntenin (EPR8102, #ab133267, Abcam), GM130 (35/
GM130, #610823, BD Transduction Laboratories) or
Tubulin (DM1A, #05–829, Millipore). HRP-labelled
secondary antibodies were purchased from Santa Cruz
Biotechnology (#sc-2004, #sc-2005, #sc-2006).
Isolation of MV and Exo
MV from cell culture supernatants were isolated as
described previously [5]. Briefly, cancer cells or
human macrophages were cultured for 48 h in RPMI-
1640 supplemented with 10% or 1%, respectively, vesi-
cle-depleted FCS (ultracentrifuged 16 h at 110,000g and
filtered through a 0.2 µm filter). Supernatants were
collected and spun down at 750g for 5 min followed
by 1500g for 15 min to remove residual cells and
debris. MV were pelleted at 14,000g, 4°C for 35 min,
washed once with PBS, and stored at −20°C in PBS.
MV derived from red blood cells and platelets were
isolated from outdated (<2 days) erythrocyte or platelet
concentrates, respectively, according to the described
protocol. The concentration of MV was measured with
a Lowry Dc protein assay (Bio-Rad).
In order to isolate EV from cancer patients and
controls, 5–15 ml peripheral blood were collected in
tubes containing EDTA (1.6 mg/ml blood, Sarstedt).
To obtain plasma samples, the blood was centrifuged
for 15 min at 1200g and passed through a valve filter
(Seraplas, Sarstedt). Plasma was centrifuged for 15 min
at 1500g and stored at −20°C. For the isolation of MV,
samples were thawed slowly at room temperature and
MV pelleted using ultracentrifugation as described
above. In order to isolate Exo, the supernatant of the
MV centrifugation step was filtered through a 0.2 µm
filter and ultracentrifuged at 110,000g, 4°C for 2 h. EV
were washed once in PBS, re-suspended in 50–500 µl
PBS and stored at −20°C in a liquid biobank. In order
to prevent any degradation of EV, plasma was pro-
cessed within 30 min of blood withdrawal.
Western blotting
Up to 30 µg of MV were subjected to SDS-PAGE and
blotted onto nitrocellulose. Membranes were blocked
for 1 h at room temperature (RT) in 5% milk powder
in TBST (137mM NaCl, 20mM Tris pH 7.6, 0.1% (v/v)
Tween-20) and incubated with specific primary anti-
bodies overnight at 4°C. After three washing steps in
Table 2. Diagnoses for the non-healthy controls.
Diagnoses* n Disease status
Aggressive lymphoma 9 In CR** > 3–21 years
Indolent lymphoma 8 In CR > 3–12 years
Indolent lymphoma 4 Watch + wait
Hodgkin’s lymphoma 1 In CR > 5 years





High-grade soft-tissue sarcoma 1 In CR > 5 years
Breast cancer 4 In CR > 5 years
Head and neck cancer 1 In CR > 1 year
Non-small-cell lung cancer 1 In CR > 8 years







Cardiomyopathy + cardiovascular disease 4
Tonsillitis 1
Liver cirrhosis 1
*Some of these patients had multiple diagnoses.
**CR = complete remission.









































TBST for 5 min each, membranes were incubated with
suitable secondary antibodies for 1 h at RT, washed
three times in TBST for 5 min each and signals
detected with ECL Prime (GE Healthcare) on a LAS-
4000 imager (Fujifilm). Ponceau staining was used as
loading control. Mean signal intensities were measured
with ImageJ version 1.48.
Flow cytometry
MV (5 µg) were blocked in 20 µl PBS + 1% vesicle-
depleted FCS for 30 min and incubated for 20 min at
RT with fluorescently-labelled antibodies and corre-
sponding isotype controls. Fluorescence was recorded
on the FACS Canto II (BD) flow cytometer and data
analysed with FACS Diva (version 6.1.3, BD) and
FlowJo (Treestar) software.
Electron microscopy
EV were pelleted as described above and fixed in 0.1M
sodium phosphate + 2% paraformaldehyde. After appli-
cation to carbon-coated EM grids (400 mesh, Plano
GmbH), they were post-fixed in 1% glutaraldehyde and
washed with dH2O. Grids were incubated for 30 s in 1%
uranyl acetate for negative contrasting. Images were
taken using a CM 120 Bio Twin transmission electron
microscope (Philips) and iTEM software (Olympus).
Nanoparticle tracking analysis (NTA)
EV size distribution and concentration were analysed
from a 500 µl sample with the Nanosight NS300
(Malvern), which was equipped with a 488 nm laser
and a sCMOS camera. Samples were measured diluted
in PBS to obtain a concentration of 20–60 particles per
frame. For each sample, three videos of 60 sec were
recorded at an automatically controlled temperature of
25°C and a syringe pump flow rate of 50. Videos were
analysed with NTA 2.3 software build 013 and used to
calculate mean values of particle concentration and size
for each sample.
Quantitative real-time PCR (qRT-PCR)
In order to analyse the effect of patient-derived MV on
immune cells in the tumour microenvironment, 1 ×
106 human macrophages were stimulated with 50 µg/
ml MV for 24 h. RNA was isolated using the High Pure
RNA isolation kit (Roche), transcribed into cDNA with
the iScript cDNA synthesis kit (Bio-Rad) and subse-
quently subjected to real-time PCR with SYBR green
detection on the 7900 HT system (Applied
Biosystems). Gene expression was normalised to the
housekeeping genes HPRT1 and GNB2L1. Primer
sequences are published in [5] and for WNT5A in [21].
Cell invasion assay and EMMPRIN blocking
peptides
Tumour cell invasion was analysed using a modified
Boyden chamber assay [22]. Briefly, 1 × 105 MCF-7 or
SK-BR-3 cells were seeded in triplicates onto an ECM-
coated polycarbonate membrane (pore diameter: 10 µm,
Pieper Filter) in the upper wells of the chamber and
grown for 96 h with/without MV stimulation (1 µg/
ml). Subsequently, the number of invasive cells in the
lower wells was counted and related to the unstimulated
control. For studies with EMMPRIN blocking peptides,
tumour cells were pre-incubated with the peptides for
2 h prior to the addition of MV. Sequences and synthesis
of the peptides are published in detail in [2].
Statistical analysis
All experiments were carried out in at least three bio-
logically independent replicates. Statistical analyses
were performed using the statistical computing soft-
ware suite R version 3.2.2 (www.r-project.org).
Population data are described as median with 95%
confidence intervals (CI). Significance was calculated
with a two-sided t test or Wilcoxon rank sum test, as
appropriate. In the case of a non-Gaussian distribution,
an estimate for the pseudomedian and the non-para-
metric confidence interval were calculated [23].
Correlations were assessed via Kendall correlation test
for ordinal associations. In survival analysis, events
were defined as cancer-related death, all other events
were considered as censored. Survival data were visua-
lised using Kaplan–Meier plots and significance was
calculated using the log-rank test for univariate ana-
lyses, stratifying the tumour antigens by a cut-off deter-
mined for an optimal separation of patients into high
and low expression groups. Hazard ratio, log-rank
p-value and number of patients in each group are
given. Univariate analyses were performed with the R
‘survival’ package (version 2.39–5) using log-rank
p-values when beta coefficients were infinite, or Wald
test p-values in all other cases [24]. Continuous values
were used when no categories were listed. To evaluate
the prognostic potential of the tumour antigens, the
receiver operating characteristic (ROC) curve was gen-
erated with the R package ‘ModelGood’ (version 1.0.9)
based on generalised linear models. The corresponding
area under the curve (AUC) values for both the total
patient cohort and indicated cancer subclasses were









































calculated. Optimal cut points of ROC curves were
determined via the Youden index with corresponding
sensitivity and specificity as stated.
Results
Isolation of total EV from peripheral blood
In order to establish a protocol to standardise the
collection of MV from human peripheral blood sam-
ples, the isolated MV and Exo were analysed under an
electron microscope, which revealed two morphologi-
cally distinct vesicle populations (Figure 1(a)). While
MV consisted of a heterogeneous cohort of vesicles
with a diameter >100 nm, Exo were more homogenous
and displayed a typical cup-shaped morphology with a
diameter of <100 nm. These observations are in accor-
dance with the current definition of the different vesi-
cle populations [1,2]. The difference in size distribution
was confirmed by nanoparticle tracking analysis
(Supplementary Figure 1(a)). Moreover, standard mar-
kers of MV and Exo were expressed in the expected
differential pattern in the two populations, while both
were negative for intracellular proteins associated with
compartments other than the plasma membrane or
endosomes [25] such as GM130 as marker for the
Golgi [26] or HDAC as marker for the nuclear com-
partment [27] (Figure 1(b)). Next, we tested the influ-
ence of pre-analytical variables, such as added
anticoagulant as well as storage conditions, on MV
quantity and composition. Comparative analysis of
MV preparations out of either EDTA or lithium hepar-
inate plasma from the same patient yielded better
results with EDTA. Lithium heparinate seemed to pro-
mote the aggregation of platelet-derived MV and
resulted in reduced MV protein yields as well as a
decrease in total and especially platelet MV counts
(Supplementary Figure 1(b–e)). While MV prepara-
tions from fresh plasma samples tended to contain
slightly more platelet-derived MV, we detected no
influence of short term (2 weeks) or long term
(6 months) storage of plasma at −20°C on MV quantity
and distribution (Supplementary Figure 1(f–i)).
MV populations in the blood of cancer patients and
controls
MV were prepared from EDTA blood samples from
cancer patients with locally advanced and/or metastatic
disease resulting from various types of solid tumours
(n = 330; Table 1), healthy individuals (n = 62; Table 1)
and non-healthy patients (n = 41; Table 2). To inves-
tigate and compare MV subpopulations in the blood of
cancer and healthy individuals, we next aimed to find
suitable markers for MV shed by the different cell
populations present in blood. Although MV are
thought to reflect the protein composition of their
cell of origin, protein export to these vesicles seems to
undergo specific sorting procedures and thus not all
cellular proteins are indeed expressed on MV [28].
While CD62E has already been established as a suitable
marker for endothelial-cell-derived MV [29], markers
for the other MV populations remain under discussion.
We therefore characterised MV derived from the main
blood cell populations. Flow cytometry revealed that
CD235a, CD62P and CD45, as markers for red blood
cells, platelets and leukocytes, are highly and specifi-
cally expressed on the respective MV populations and
enable their discrimination in complex MV mixtures
(Figure 2(a–c)).
Since several studies have described an elevated
number of vesicles in the blood of tumour patients
compared to healthy controls [11,30,31], we first
Figure 1. Isolation of MV from peripheral blood. (a) Isolated MV and Exo from two donor samples were visualised by electron
microscopy (TEM) revealing two morphologically different vesicle populations. (b) Representative western blot of at least three
independent samples for common vesicle markers. CX = whole cell lysate from HeLa cells.


















































































Figure 2. Comparison of blood-cell-derived MV in cancer and control patients. (a–c) Flow cytometry analysis of specific markers for MV
isolated from red blood cells, platelets and leukocytes (macrophages) (CD235a, CD62P, CD45: grey filled; respective isotype control: black
line) (n = 3). (d) MV concentrations per ml plasma were determined by quantification of MV protein yield. (e) Flow cytometry: Comparison of
the percentage of CD235a-, CD62P-, CD45- and CD62E-positive MV in blood from either cancer patients or healthy and non-healthy controls
(*p = 0.037, **p = 0.023, two-sided t test). Boxplots depict the median (line), the 25–75 percentiles (box) and the 10–90 percentiles
(whiskers). (f) Summary of the analysis of blood-cell-derived MV by flow cytometry. Significance was calculated with a two-sided t test or
Wilcoxon rank sum test, as appropriate. *Indicates median calculation with [23].









































measured the overall MV concentrations via quantifi-
cation of MV protein yield in our large study group.
However, we did not observe any significant increase
in the total amount of MV in cancer patients’ blood
(healthy: median 59.09; 95% CI 49.83–70.85, cancer:
median 54.01; 95% CI 49.89–58.51 µg MV/ml plasma)
(Figure 2(d)). Using our established markers, we then
analysed the composition of blood cell-derived MV in
cancer patients and controls (Figure 2(e,f)). In corre-
spondence with previous reports [32,33], we detected
the largest portion of blood-borne MV to be derived
from platelets. The number of platelet-derived,
CD62P+ MV was slightly, but significantly increased
in cancer versus non-healthy control patients which
might at least partially be due to slightly lower platelet
and leukocyte counts in the latter (Supplementary
Table 1). The same trend was observed for leukocyte-
derived CD45+ MV. In contrast, we did not detect
changes in the numbers of CD235a+ or CD62E+ MV.
Furthermore, there were no significant abnormalities
in blood cell counts of the cancer patients which could
have influenced the results (Supplementary Table 1).
Identification of T-MV in the blood of cancer
patients
Next, we asked whether it is possible to detect T-MV
within the mixture of blood-derived MV without any
further selection or purification procedures which are
time-consuming, may lead to loss of vesicles, and are
therefore not suitable for routine diagnostics. First, we
screened T-MV from five different tumour-cell lines
(MCF-7, SK-BR-3, MDA-MB-231, A549, SW480) by
flow cytometry for the expression of the proteins
EpCAM, EGFR, MUC1, EMMPRIN/CD147, and CD47
(Figure 3, Supplementary Figure 2(a)). These proteins are
often overexpressed in tumours and are often used as so-
called tumour markers [2,34–36]. Among them, only
CD47 and EMMPRIN were expressed ubiquitously on
T-MV from all the analysed cell lines. In contrast, the
other proteins were expressed in a way specific to tumour
subtype, indicating their potential benefit in the detection
of specific cancer types, such as MUC1 for breast cancer.
T-MV did not express the Exo marker CD63, thus ruling
out significant contaminations with this vesicle popula-
tion (Supplementary Figure 2(b)).
We next analysed these markers in the samples from
our vesicle biobank. Flow cytometry revealed that
EMMPRIN+ as well as EpCAM+ MV were significantly
elevated in the blood of cancer patients versus healthy and
non-healthy controls (Figure 4(a), Table 3). Among the
different cancer subgroups, EpCAM+ MV were increased
especially in head&neck and breast cancer, but less in lung
and colorectal cancer patients. EGFR+ MV were only
elevated in comparison to non-healthy control patients,
although there was also a trend towards an increase in
comparison with the healthy controls. Higher levels of
EGFR+ MV were observed in particular in colorectal can-
cer patients. Interestingly, the percentage of MUC1+ MV
was elevated in non-healthy patients resulting in a signifi-
cant difference only between healthy individuals and can-
cer patients. The increase in EGFR+ and MUC1+ MV
present in cancer patients’ blood was also confirmed by
western blotting (Figure 4(b,c)). CD47 proved unsuitable
as a discriminator since it was expressed equally (>90%
positive MV) in all the samples investigated and did not
demonstrate any significant difference between cancer and
control patients (Supplementary Figure 2(c)).
While EpCAM+, EGFR+ and MUC1+ MV were barely
detectable in control samples, EMMPRIN+ MV were
present in all the samples investigated. This is because
of its presence also on benign MV derived from platelets
or leukocytes (Supplementary Figure 2(d)). In contrast,
none of the other proteins was present on MV derived
from blood cells (Supplementary Figure 2(e)), thus
underlining their specificity for T-MV. In order to con-
firm that the increase in the MV-associated tumour anti-
gens in cancer patients’ blood does indeed reflect the
presence of MV shed by tumour cells, we performed
double staining with EMMPRIN and either EGFR or
MUC1 as a second marker. Consistently, the EGFR+
and MUC1+ MV also stained positive for EMMPRIN.
This population of either EGFR+/EMMPRIN+ or
MUC1+/EMMPRIN+ MV was significantly elevated in
cancer patients and almost undetectable in controls
(Figure 4(d,e)), thereby again underlining the tumour
specificity of these markers.
Higher glycosylated EMMPRIN is detected
predominantly on cancer patients´ MV
Previously, we identified the presence of three different
EMMPRIN glycoforms on MV of which only the very
highly-glycosylated variant (HG-EMMPRIN,
50–65 kDa) with N-glycosylation at the residues N160
and N268 is expressed on pro-invasive MV mediating
tumour cell invasion [2]. Consistently, this glycoform
was detectable only on whole-blood-derived MV from
cancer patients, whereas the intermediately glycosy-
lated form (IG-EMMPRIN, 45–50 kDa) which is not
pro-invasive [2] was present in all samples (Figure 5
(a)). This further supports our hypothesis that the
observed increase in EMMPRIN+ MV in cancer
patients is indeed due to the presence of T-MV and
not to a reactive increase in MV derived from benign
cells such as platelets or leukocytes.









































Cancer-patient-derived MV enhance tumour cell
invasion ex vivo dependent on EMMPRIN
glycosylation
Since in vitro T-MV enhance the invasiveness of
tumour cells, we tested whether the whole mixture of
cancer patient-derived MV exerts a similar effect ex
vivo. Indeed, MV from cancer patients strongly
enhanced the invasion of MCF-7 and SK-BR-3 breast
cancer cells, whereas MV from control patients had no
such effect (Figure 5(b)). Moreover, MV from cancer
patients with a very high number of EMMPRIN+ MV
(>35%) enhanced tumour cell invasion more strongly
than MV from patients with a lesser EMMPRIN con-
tent (Figure 5(c)). Tumour cell invasion induced by
cancer-patient-derived MV was efficiently antagonised
by specific blocking peptides directed against the two
glycosylation sites N160 and N268 [37], whereas ran-
dom control peptides had no such effect (Figure 5(d)).
Taken together, this underlines the assumption that
T-MV in cancer patients’ blood are able to promote
disease progression by increasing the invasiveness of
cancer cells through HG-EMMPRIN.
Cancer-patient-derived MV influence macrophages
towards a tumour-supporting phenotype
Considering that T-MV have been shown to influence
surrounding immune cells [5–7], we aimed to
Figure 3. Flow cytometry analysis of in vitro T-MV reveals EMMPRIN and CD47 as general markers of T-MV. MV were isolated from
five cancer cell lines and characterised for the expression of known markers (grey filled) by flow cytometry (n ≥ 3). The respective
isotype control is depicted as a black line.









































investigate whether patient-derived MV can also foster
the creation of a favourable tumour microenvironment
essential to progression and metastasis formation. We
thus stimulated human macrophages ex vivo with MV
from cancer patients and controls and analysed their
influence on the expression of several activation and
polarisation genes (Figure 6(a)). MV from cancer
patients induced high expression of vascular
Figure 4. A panel of MV-associated proteins identifies T-MV in cancer patients’ blood. (a) The percentage of EpCAM-, EMMPRIN-,
MUC1- and EGFR-positive MV in whole blood was measured by flow cytometry. The four last boxes illustrate the results for the four
largest cancer subgroups within the cohort. Exact values are given in Table 3. P-values were calculated with a Wilcoxon rank sum
test. (b, c) Western blot analysis of EGFR and MUC1 expression in cancer- and control-patient-derived MV. Ponceau staining is
depicted as loading control. (d, e) Flow cytometry: double staining of cancer- and control-patient-derived MV for EMMPRIN/MUC1
and EMMPRIN/EGFR. Gates were set based on the respective isotype control. Boxes mark the 25–75 percentiles (line at median) and
whiskers the 10–90 percentile. *p = 6.852e-06, **p = 2.015e-06 (Wilcoxon rank sum test).









































endothelial growth factor (VEGF), a factor promoting
angiogenesis [38], as well as WNT5A and interleukin 1
beta (IL1B), which are known to drive macrophages
into a tumour-supporting phenotype [39–41]. Since the
upregulation of WNT5A mRNA did not quite reach
significance (p = 0.0796) due to the high range of
values, the WNT5A induction was additionally con-
firmed on the protein level (Figure 6(b)). These find-
ings suggest that T-MV in cancer patients’ blood have a
strong effect on benign stroma cells and can support
the creation of a favourable microenvironment.
T-MV in cancer patients’ blood are prognostic for
clinical outcome
Based on these findings, our next step was to determine
whether the presence of T-MV is associated with clin-
ical outcome. We thus investigated into whether the
amount of MUC1+, EGFR+, EpCAM+ or EMMPRIN+
MV was correlated with OS in the total study cohort.
Interestingly, in spite of the diversity of cancer sub-
types, a large number of EMMPRIN+ MV (>29.1%
positive MV) significantly correlated with shorter OS
(hazard ratio (HR) 1.46, 95% CI 1.06–2.03, p = 0.021)
(Figure 7(a)). This was supported by univariate ana-
lyses (Supplementary Table 2). The number of
EMMPRIN+ MV in blood was especially increased in
advanced tumour stages (Kendall’s tau coefficient:
0.1516, p = 0.005) (Supplementary Figure 3).
Accordingly, univariate analyses confirmed that the
number of EMMPRIN+ MV in blood is independent
of age or gender but influenced by the tumour stage
(Supplementary Table 3). As regards the other anti-
gens, none of them proved prognostic in the total
study cohort. However, as the in vitro screening of
T-MV (Figure 3) and the analysis of patient samples
(Figure 4(a)) had already suggested, EpCAM, EGFR
and MUC were not expressed on all cancer cells, but
only on specific cancer subtypes. Taking this into con-
sideration, we focused on the four largest cancer sub-
classes in our cohort, i.e. head and neck, lung, breast
and colorectal cancer. There, we were able to demon-
strate that an elevated number of MUC1+ MV is asso-
ciated with an unfavourable prognosis in head and
Table 3. Analysis of tumour MV in cancer patients.
Marker
% positive MV
median [95% CI] p-value
EMMPRIN
Healthy 27.70 [25.00–29.25] 8.215e-06
Non-healthy 26.45 [24.61–29.96] 0.003
Cancer 31.75 [30.70–32.35] 7.062e-08
head & neck cancer 30.65 [29.45–32.20] 1.589e-04
lung cancer 31.85 [30.95–33.95] 4.523e-07
breast cancer 31.70 [29.10– 32.90] 0.001
colorectal cancer 32.90 [29.30–34.20] 7.945e-04
EGFR
Healthy 2.20* [1.25–3.35] 0.065
Non-healthy 1.50* [0.55–4.15] 0.008
Cancer 3.20* [2.65–3.75] 0.002
head & neck cancer 3.15* [2.10–4.05] 0.002
lung cancer 2.95* [1.85–4.10] 0.080
breast cancer 3.50* [2.25–4.85] 0.037
colorectal cancer 3.25* [1.90–4.95] 0.005
EpCAM
Healthy 1.80* [1.20–2.65] 1.716e-06
Non-healthy 2.78* [1.60–4.15] 0.008
Cancer 3.60* [3.15–4.05] 2.079e-07
head & neck cancer 3.65* [3.00–4.30] 6.227e-07
lung cancer 3.20* [2.30–4.10] 0.006
breast cancer 3.80* [2.65–5.00] 5.860e-07
colorectal cancer 3.95* [2.50–5.35] 0.003
MUC1
Healthy 1.75* [1.30–2.40] 3.015e-06
Non-healthy 2.30* [1.91–3.83] 0.399
Cancer 2.90* [2.50–3.35] 9.920e-07
head & neck cancer 2.55* [2.05–3.35] 2.934e-05
lung cancer 3.51* [2.74–4.20] 3.020e-06
breast cancer 3.08* [2.15–4.50] 2.916e-04
colorectal cancer 2.10* [1.44–2.95] 0.004
Significance was calculated for healthy and non-healthy controls versus all cancer patients and for cancer patients and cancer subgroups versus all controls
(healthy/non-healthy). Only for MUC1, significance for cancer subgroups was calculated versus healthy controls due to the reactive increase of MUC+ MV in
non-healthy patients. *Indicates median calculation with [23].

















































































Figure 6. Cancer-patient-derived MV induce a tumour-supporting phenotype in human macrophages. (a) Human macrophages
were stimulated with MV isolated from cancer or control patients (50 µg/ml) for 24 h and gene expression of VEGFA, WNT5A and
IL1B was measured by qRT-PCR (n = 4, *p = 0.004, **p = 0.041 with two-sided t test). Expression changes were calculated relative to
unstimulated macrophages. Box plots illustrate the 25–75 percentiles (boxes), the 10–90 percentiles (whiskers) and the median
(line). (b) Representative western blot of four independent experiments: Wnt5a expression in unstimulated macrophages (ctl) and







































Figure 5. Highly-glycosylated EMMPRIN is enriched on cancer-patient-derived MV and mediates tumour invasion. (a) Western blot
analysis of EMMPRIN glycoforms on MV derived from cancer or control patients. Ponceau staining is depicted as loading control. In
the last control sample (first lane on the right), in vitro T-MV derived from MCF-7 cells were added to demonstrate the increase of
HG-EMMPRIN in the presence of tumour-derived MV. HG-EMP = highly-glycosylated EMMPRIN, IG-EMP = intermediately-glycosy-
lated EMMPRIN. Western blot images depict one representative of five independent experiments. Histograms represent mean signal
intensities ± SD of HG- and IG-EMP in the MV analysed by western blot. *p = 0.035 with Wilcoxon rank sum test. (b) Boyden
chamber assays of MCF-7 and SK-BR-3 cells stimulated for 96 h with 1 µg/ml MV derived from cancer or control patients (n = 14 for
MCF-7, n = 4 for SK-BR-3, mean±SD, *p = 3.288e-17, **p = 7.833e-10 with two-sided t test). Invasion was calculated compared to
unstimulated cells (ctl). (c) Invasiveness of MCF-7 cells either unstimulated (ctl) or in the presence of 1µg/ml MV derived from cancer
patients with a high (>35%) or low (<35%) percentage of EMMPRIN+ MV in blood (n = 14, mean±SD, *p = 8.652e-17, **p = 4.379e-
23, ***p = 0.031 with two-sided t test). (d) Boyden chambers: MCF-7 cells were pre-incubated for 2 h with or without (=ctl) specific
blocking peptides directed towards N160 (P-N160) and N268 (P-N268) or random control peptides (P-N160rd and P-N268rd) and
then stimulated with 1 µg/ml cancer-patient-derived MV (n = 10, mean±SD, *p = 7.722e-05, **p = 1.075e-03 with two-sided t test).


















































































































































































































































































































































































neck (HR 2.32, 95% CI 1.03–5.25, p = 0.037), lung (HR
2.18, 95% CI 1.27–3.74, p = 0.004), as well as breast
(HR 3.06, 95% CI 1.26–7.4, p = 0.009) cancer (Figure 7
(b–d)). MUC1 had no prognostic value in colorectal
cancer, since it is rarely present on MV from these
patients. Instead, colorectal cancer patients often dis-
played an elevated number of EGFR+ MV (Figure 4(a))
which significantly correlated with shorter survival
(HR 3.32, 95% CI 1.22–9.0, p = 0.013) (Figure 7(e)).
The presence of EpCAM+ MV was prognostic in all
four cancer subclasses (Figure 7(b–e)). The discrimina-
tive power of these MV-associated tumour antigens
was assessed using receiver operating characteristics
(ROC) curves. None of the antigens alone was able to
separate reliably cancer patients from healthy indivi-
duals in the total study cohort as well as in the four
largest cancer subgroups, predominantly owing to a
rather low sensitivity. The combination of all four
markers, however, markedly enhanced sensitivity and
discriminated between these cohorts with a high AUC
of 0.83–0.85 (Figure 7(f,g)). The specificity for the
mentioned markers either alone or in combination
was rather high and mostly >0.8. Taken together, this
demonstrates that through the definition of suitable
antigens, MV can be employed as valuable prognostic
biomarkers in cancer.
Discussion
This study provides the first detailed analysis of MV
subpopulations in cancer patients’ blood with particu-
lar emphasis on the characterisation of T-MV within
the whole MV mixture. These T-MV can be identified
by using a simple flow cytometric approach through
the combination of different antigens without any
further sorting procedures. Although T-MV represent
only a minor percentage of the whole MV population,
their presence is associated with poor patient out-
comes. The finding that these blood-borne MV
strongly promote tumour cell invasion and influence
the phenotype of immune cells ex vivo further high-
lights their function in cancer progression.
We focused on the analysis of MV in blood since they
are larger than Exo and can thus be isolated much faster
from a small amount of blood with routine table-top
centrifuges and subsequently be analysed by flow cyto-
metry. Although several groups are working on the estab-
lishment of alternative MV and Exo isolation methods
using specific capture assays or micro-nuclear magnetic
resonance (µNMR) chips [19,42,43], these methods are
expensive, require specialised equipment, and are thus
not yet suitable for use in routine clinical diagnostics.
Standard flow cytometry only allows the analysis of
vesicles with a diameter >200–300 nm, meaning that
some smaller MV might evade detection. Nevertheless
our results confirm that this method is still sufficient to
identify and characterise T-MV in whole blood. While
some studies have described the presence of large onco-
somes (diameter 1–10 µm) carrying tumour antigens in
the circulation of mice with metastatic disease and
patients with prostate cancer [44,45], we never found
any vesicles larger than 800 nm in our MV preparations.
Therefore, we believe that MV and large oncosomes are
two different vesicle populations, although they might
share overlapping functions or show similar protein
expression patterns, considering that they both bud off
directly from the plasma membrane.
We identified EMMPRIN/CD147 as a marker gener-
ally expressed on T-MV. Consistently, far more
EMMPRIN+ MV were present in the blood of cancer
versus healthy as well as non-healthy controls, proving
prognostic in spite of the heterogeneity of our study
cohort. Although EMMPRIN is also expressed on plate-
let- or leukocyte-derived MV, we did not detect any
significant increase in these MV populations in cancer
patients’ blood compared to healthy individuals. This
supports our hypothesis that the increase in
EMMPRIN+ MV numbers is indeed due to the presence
of T-MV. This hypothesis was further corroborated by
double staining with EMMPRIN and other tumour anti-
gens. Of note, we found highly-glycosylated EMMPRIN
only on cancer-patient-derived MV and not on controls.
Previously, we identified this glycoform as one of the
proteins responsible for the pro-invasive function of
T-MV [2]. Using specific blocking peptides, this was
also confirmed for cancer patients’ MV.
The numbers of MUC1+, EGFR+ or EpCAM+ MV
were also elevated in cancer patients’ blood. However,
their prognostic value with respect to OS was restricted
to specific cancer subtypes. This is not surprising,
considering the subtype-specific expression pattern of
these antigens. Although we were able to demonstrate
that the number of EMMPRIN+ MV was positively
correlated with poor survival in general, analysis of
EMMPRIN or of other individual markers alone was
not sufficiently sensitive to reliably separate cancer
patients with different tumour entities from healthy
individuals. However, as shown by ROC analysis, sen-
sitivity was markedly increased and an accurate discri-
mination was achieved by combining all four antigens.
Similar observations were made in another study,
which demonstrated that only the combination of
EGFR, EGFRvIII, Podoplanin (PDPN) and mutated
isocitrate dehydrogenase 1 (IDH1) was able to distin-
guish glioblastoma-derived EV from host-derived EV
efficiently [19]. T-MV often harbour several tumour-









































specific antigens, which are easily and simultaneously
accessible via multicolour flow cytometry. This pro-
vides us with the opportunity to identify tumour-spe-
cific or even patient-specific signatures, which may
prove to be of higher sensitivity and specificity than
measurement of the classic serum tumour markers.
The present study involved mostly patients with
late-stage tumours and/or metastatic disease, since we
assumed that the expected larger number of T-MV in
advanced stages would facilitate the establishment of
our methods as well as the identification of marker
profiles. Based on these results, it will now be interest-
ing to evaluate whether the tumour antigens identified
also facilitate early disease detection as well as which
combinations of markers are beneficial in the detection
of specific cancer subtypes.
Although several studies in mice have already sug-
gested that T-Exo can strongly promote disease pro-
gression by educating cells derived from bone marrow
towards a pro-metastatic phenotype [8] and preparing
lymph nodes for metastasis formation [9,10], data on
similar effects in human cancer patients are still scarce.
In our study we now provide the first hints that not
only T-Exo, but also T-MV are important in tumour
progression. On the one hand, we observed that MV
from cancer patients promoted tumour cell invasion ex
vivo; on the other hand they initiated a tumour-sup-
porting phenotype in human macrophages by inducing
the expression of WNT5A, IL1B and VEGFA. These
effects were not observed for MV derived from con-
trols. Upregulation of VEGFA and WNT5A is known
to increase endothelial cell proliferation, migration and
activity [46,47], thereby suggesting some potential
angiogenesis-promoting effect of T-MV. Furthermore,
WNT5A can upregulate C-C motif chemokine ligand 2
(CCL2) expression in myeloid cells which would enable
the recruitment of more macrophages [48] that are
known to mediate pre-metastatic site formation [49].
In vitro studies of IL1B have revealed protumoural
effects by revealing that colorectal cancer cells can
induce the release of IL1B from surrounding macro-
phages, which then acts back on the tumour cells and
activates canonical WNT signalling in support of
tumour growth [39]. Taken together, these results sug-
gest that MV promote tumour invasion as well as the
creation of a favourable tumour niche in vivo, which
favours disease progression and metastasis formation.
Therefore, it is not surprising that all the patients in
our study with large numbers of MV carrying tumour
antigens (EMMPRIN, MUC1, EGFR or EpCAM) had a
significantly shorter OS.
In conclusion, we show that with the use of a combi-
nation of different antigens, T-MV can be reliably
detected within the mixture of MV in cancer patients’
blood by flow cytometry without any further purification
process. Since the presence of these MV is associated with
clinical outcome, they seem promising as novel prognos-
tic biomarkers in cancer, especially upon characterisation
with multiple markers. Our study also provides new
insight into the pro-invasive MV function via their influ-
ence on the tumour microenvironment, which suggests a
role as potential targets in novel anti-cancer therapies.
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